Compare Oatly Group AB - ADR (OTLY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Tango Therapeutics Inc. — how do they compare? Oatly Group AB - ADR trades at $11.1 (market cap $347.84M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 10.8× Oatly Group AB - ADR's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Tango Therapeutics Inc. for 0 Days on average.
| OTLY | TNGX | |
|---|---|---|
Market Cap | $347.84M | $3.75B |
Volume | 116,933 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $32.90 |
52-Week Low | $8.03 | $7.50 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $852.26M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $11.15, up 4.5% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $862M in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Recent Q2 2026 results beat expectations and management raised full-year revenue guidance, driving positive sentiment.
While OTLY demonstrates operational progress with margin improvement and revenue acceleration, significant risks remain including persistent losses, high debt levels, and negative cash flow. Analyst consensus is mixed with 44% buy ratings but a modest $12.28 price target suggesting limited upside from current levels amid ongoing profitability challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
